This article is general information and news, not medical advice or an advert. Weight-loss medicines are prescription-only, and whether one is right for you is a decision for a qualified prescriber.
For years, GLP-1 weight-loss medicines have meant a weekly injection. That's now changing. A daily tablet version of semaglutide, the same medicine inside Wegovy, has been approved, and as of June 2026 it has a UK licence. If needles have been the thing putting you off, this is a genuinely new option to understand. Here's what it is, how well it works, and where UK access actually stands.
Quick answer: the "Wegovy pill" is a once-daily 25 mg oral semaglutide tablet. It was approved in the US in December 2025 and licensed by the UK's MHRA in June 2026, but it is not on the NHS yet. In trials it produced around 14 to 17% weight loss, similar to the injection. The catch is a strict daily routine: empty stomach, a sip of water, then nothing for 30 minutes.
What's new
The new product is a high-dose oral form of semaglutide for weight management. The US Food and Drug Administration approved it in December 2025, and it reached US pharmacies in January 2026 (Novo Nordisk, December 2025). In the UK, the MHRA approved it on 11 June 2026, the first GLP-1 tablet licensed here for weight management. The MHRA was careful to add that approval does not mean NHS availability, which follows a separate process, including an evaluation by NICE (MHRA, June 2026). In Europe, the regulator's committee gave a positive opinion in May 2026, with a final decision still to come (EMA, May 2026).
Wait, isn't there already an oral semaglutide?
There is, and it's a common point of confusion. Rybelsus is an oral semaglutide tablet that's been around since 2019, but at lower doses (3, 7 and 14 mg) and licensed for type 2 diabetes, not weight loss (Rybelsus SmPC). The new Wegovy pill is the same molecule taken up to a much higher 25 mg, and licensed specifically for weight management. Same drug family, different dose, different job.
How well it works
In its main weight-loss trial, the 25 mg pill led to roughly 14% average weight loss across everyone in the study, and around 17% in those who kept taking it, over about 15 months (OASIS 4, NEJM 2025). For comparison, the weekly Wegovy injection produced about 15% in its main trial (STEP 1, NEJM 2021), and tirzepatide (Mounjaro) reached around 21 to 22% at its top dose (SURMOUNT-1, NEJM 2022). So the pill is broadly in line with the Wegovy injection, while Mounjaro remains the most effective option. One honest note: these are separate trials with different participants, so the comparison is indirect rather than head-to-head.
Pill vs injection in practice
The big trade-off isn't really about how well it works. It's about the daily routine. Oral semaglutide is poorly absorbed, so it comes with strict instructions: take it first thing in the morning on an empty stomach, after fasting for at least eight hours, swallowed whole with no more than a small sip of water, and then nothing else by mouth, no food, drink or other tablets, for at least 30 minutes (MHRA, June 2026).
That's a daily commitment, and it's easy to slip up on a busy morning. The weekly injection has no food rules at all, but it does mean a jab once a week. Neither is better in the abstract. The pill may suit people who dislike needles or don't want anything in the fridge; the injection may suit people who'd rather think about it once a week than build a careful morning ritual.
Side effects
Because it's the same class of medicine, the side effects look familiar. The common ones are gastrointestinal, nausea, vomiting, diarrhoea and constipation, usually mild to moderate and most noticeable while the dose is being increased (NHS, semaglutide). As with all of these medicines, there are important safety considerations and contraindications that a prescriber checks before starting, which is exactly why it's prescription-only.
UK access, realistically
Approval and availability aren't the same thing. As of June 2026 the pill is licensed in the UK but not funded on the NHS, and NHS use will depend on a NICE appraisal that hasn't happened yet (MHRA). For context, the Wegovy injection is only offered on the NHS through specialist weight-management services and for up to two years (NICE TA875). Early access to the pill is expected to be private, and pricing is still settling. This is a fast-moving area, so the picture may well have moved on by the time you read this.
Whichever form you're on, track it properly
Healthcount lets you log your dose, weight and how you feel, whether you're on a weekly injection or a daily tablet, so you can see what's working over time.
Try the free macro counterFAQs
Is there a Wegovy pill?
Yes, a once-daily 25 mg oral semaglutide tablet. It was approved in the US in December 2025 and licensed in the UK in June 2026.
When can I get it on the NHS?
Not yet. NHS use needs a separate NICE appraisal, which hasn't happened. Early UK access is expected to be private.
Is the pill as effective as the injection?
Roughly, yes. Trials show similar weight loss to the Wegovy injection, while Mounjaro remains the most effective option. Suitability is always a clinician's decision.
